整形外科インプラント向け黄色ブドウ球菌感染症診断・治療の世界市場：診断&治療区分・エンドユーザー・地域別の予測 (～2032年)

整形外科インプラント向け黄色ブドウ球菌感染診断・治療の市場規模は、2022年の23億1,000万米ドル、2023年の24億米ドルから、予測期間中は4.89％のCAGRで推移し、2032年には38億7,000万米ドルの規模に成長すると予測されています。になると予測されます。

インプラントを使用する整形外科手術の増加と骨折の発生率の増加が市場拡大の原動力となっています。

整形外科手術の増加により、整形外科用インプラントに向けた黄色ブドウ球菌感染診断・治療の需要が高まっています。例えば、2023年7月、Cleveland Clinic (米国) は、米国では年間約80万件の人工膝関節置換術が行われていると発表しました。さらに、American Association of Hip and Knee Surgeonsは、人工股関節全置換術 (THA) 後の深刻な懸念事項として人工関節感染症 (PJI) を挙げており、特に他の健康問題が存在する場合はリスクが高まるとしています。黄色ブドウ球菌による感染症の割合は、2008～2009年の26.3％から2020～2021年には40％に増加しています。

地域別インサイト

2022年には、北米市場が最大のシェアを占めました。これは、整形外科インプラントにおける黄色ブドウ球菌感染症の有病率の増加、優れたヘルスケアインフラ、北米における整形外科手術件数の増加に関連しています。

当レポートでは、世界の整形外科インプラント向け黄色ブドウ球菌感染症診断・治療の市場を調査し、市場の定義と概要、市場成長への各種影響因子の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

• 促進要因
  • インプラントを伴う整形外科手術の増加
  • 骨折の発生率の増加
• 抑制要因
  • 厳しい規制要件と長い承認プロセス
• 機会
  • 整形外科関連の黄色ブドウ球菌感染症の技術的治療
  • 早期診断への意識の高まりと早期診断製品の開発

第5章 市場要因分析

• ポーターのファイブフォース分析
• COVID-19の市場への影響

第6章 世界の整形外科インプラント向け黄色ブドウ球菌感染症診断・治療市場：診断・治療区分別

• 概要
• 診断
  • 微生物培養検査
  • ポリメラーゼ連鎖反応
  • 画像研究
• 治療
  • 抗生物質
  • 抗菌療法
  • 手術

第7章 世界の整形外科インプラント向け黄色ブドウ球菌感染症診断・治療市場：エンドユーザー別)

• 概要
• 病院
• 外来手術センター
• その他

第8章 世界の整形外科インプラント向け黄色ブドウ球菌感染症診断・治療市場：地域別

• 概要
• 北米
• 欧州
• アジア太平洋
• その他の地域

第9章 競合情勢

• 市場シェア分析
• 競合ダッシュボード
• 公開企業の株式概要
• 比較分析：主要企業の財務動向
• 主な展開・成長戦略

第10章 企業プロファイル

• XELLIA PHARMACEUTICALS
• WELLONA PHARMA
• SCHWITZ BIOTECH
• MERCK KGAA
• THERMO FISHER SCIENTIFIC INC
• BIOMERIEUX SA
• SIEMENS HEALTHINEERS AG
• BECKMAN COULTER INC
• F. HOFFMANN-LA ROCHE LTD
• PFIZER INC

第11章 データの引用

LIST OF TABLES

• TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT
• TABLE 2 INDICATIVE SHARE (%) FOR IMPLANTS AFFECTED BY STAPHYLOCOCCUS AUREUS BY REGION, (2022)
• TABLE 3 TOTAL NUMBER OF JOINT REPLACEMENTS AND COMPLICATED FRACTURES REPAIRED WITH PLATES AND SCREWS BY GLOBAL, 2019-2023
• TABLE 4 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED, BY GLOBAL, 2019-2023
• TABLE 5 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED WITH STAPHYLOCOCCUS AUREUS (SA) INFECTION BY GLOBAL, 2019-2023
• TABLE 6 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS REVISED SURGERIES ARE DONE BASED ON AN SA INFECTION BY GLOBAL, 2019-2023
• TABLE 7 TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES AND TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES INFECTED WITH SA BY GLOBAL, 2019-2023
• TABLE 8 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 9 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY REGION, 2019-2032 (USD BILLION)
• TABLE 10 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 11 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR MICROBIOLOGICAL CULTURE TEST, BY REGION, 2019-2032 (USD BILLION)
• TABLE 12 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR POLYMERASE CHAIN REACTION, BY REGION, 2019-2032 (USD BILLION)
• TABLE 13 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY REGION, 2019-2032 (USD BILLION)
• TABLE 14 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 15 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR COMPUTED TOMOGRAPHY (CT), BY REGION, 2019-2032 (USD BILLION)
• TABLE 16 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR MAGNETIC RESONANCE IMAGING (MRI), BY REGION, 2019-2032 (USD BILLION)
• TABLE 17 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR ULTRASONOGRAPHY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 18 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY REGION, 2019-2032 (USD BILLION)
• TABLE 19 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 20 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR ANTIBIOTICS, BY REGION, 2019-2032 (USD BILLION)
• TABLE 21 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR ANTIMICROBIAL THERAPY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 22 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR SURGERY, BY REGION, 2019-2032 (USD BILLION)
• TABLE 23 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 24 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR HOSPITALS, BY REGION, 2019-2032 (USD BILLION)
• TABLE 25 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR AMBULATORY SURGERY CENTERS, BY REGION, 2019-2032 (USD BILLION)
• TABLE 26 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR OTHERS, BY REGION, 2019-2032 (USD BILLION)
• TABLE 27 GLOBAL: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION, 2019-2032 (USD BILLION)
• TABLE 28 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 29 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 30 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 31 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 32 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 33 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 34 US: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 35 US: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 36 US: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 37 US: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 38 US: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 39 CANADA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 40 CANADA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 41 CANADA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 42 CANADA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 43 CANADA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 44 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 45 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 46 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 47 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 48 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 49 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 50 GERMANY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 51 GERMANY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 52 GERMANY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 53 GERMANY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 54 GERMANY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 55 FRANCE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 56 FRANCE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 57 FRANCE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 58 FRANCE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 59 FRANCE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 60 UK: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 61 UK: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 62 UK: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 63 UK: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 64 UK: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 65 ITALY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 66 ITALY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 67 ITALY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 68 ITALY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 69 ITALY: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 70 SPAIN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 71 SPAIN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 72 SPAIN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 73 SPAIN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 74 SPAIN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 75 REST OF EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 76 REST OF EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 77 REST OF EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES BY TYPE, 2019-2032 (USD BILLION)
• TABLE 78 REST OF EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR TREATMENT, BY TYPE 2019-2032 (USD BILLION)
• TABLE 79 REST OF EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER 2019-2032 (USD BILLION)
• TABLE 80 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY COUNTRY, 2019-2032 (USD BILLION)
• TABLE 81 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 82 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 83 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 84 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 85 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 86 CHINA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 87 CHINA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 88 CHINA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 89 CHINA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 90 CHINA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 91 INDIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 92 INDIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 93 INDIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 94 INDIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 95 INDIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 96 JAPAN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 97 JAPAN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 98 JAPAN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 99 JAPAN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 100 JAPAN: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 101 SOUTH KOREA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 102 SOUTH KOREA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 103 SOUTH KOREA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 104 SOUTH KOREA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 105 SOUTH KOREA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 106 AUSTRALIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 107 AUSTRALIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 108 AUSTRALIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 109 AUSTRALIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 110 AUSTRALIA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 111 REST OF ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 112 REST OF ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 113 REST OF ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 114 REST OF ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 115 REST OF ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 116 REST OT THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION, 2019-2032 (USD BILLION)
• TABLE 117 REST OF THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 118 REST OF THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 119 REST OF THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 120 REST OF THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 121 REST OF THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 122 MIDDLE EAST & AFRICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 123 MIDDLE EAST & AFRICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 124 MIDDLE EAST & AFRICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 125 MIDDLE EAST & AFRICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 126 MIDDLE EAST & AFRICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 127 LATIN AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2019-2032 (USD BILLION)
• TABLE 128 LATIN AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR DIAGNOSIS, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 129 LATIN AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, FOR IMAGING STUDIES, BY TYPE, 2019-2032 (USD BILLION)
• TABLE 130 LATIN AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY TREATMENT, 2019-2032 (USD BILLION)
• TABLE 131 LATIN AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2019-2032 (USD BILLION)
• TABLE 132 PUBLIC PLAYERS STOCK SUMMARY
• TABLE 133 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• TABLE 134 PRODUCT APPROVAL
• TABLE 135 XELLIA PHARMACEUTICALS: PRODUCTS OFFERED
• TABLE 136 WELLONA PHARMA.: PRODCUTS OFFERED
• TABLE 137 SCHWITZ BIOTECH: PRODUCTS OFFERED
• TABLE 138 MERCK KGAA: PRODUCTS OFFERED
• TABLE 139 THERMO FISHER SCIENTIFIC INC: PRODUCTS OFFERED
• TABLE 140 BIOMERIEUX SA: PRODUCTS OFFERED
• TABLE 141 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
• TABLE 142 SIEMENS HEALTHINEERS AG: KEY DEVELOPMENTS
• TABLE 143 BECKMAN COULTER INC: PRODUCTS OFFERED
• TABLE 144 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
• TABLE 145 PFIZER INC: PRODUCT OFFERED

LIST OF FIGURES

• FIGURE 1 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET: STRUCTURE
• FIGURE 2 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET: MARKET GROWTH FACTOR ANALYSIS (2022-2032)
• FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)
• FIGURE 4 RESTRAINT IMPACT ANALYSIS (2022-2032)
• FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET
• FIGURE 6 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, DIAGNOSIS & TREATMENT SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
• FIGURE 7 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT, 2022 & 2032 (USD BILLION)
• FIGURE 8 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET SHARE (%), BY DIAGNOSIS & TREATMENT,
• FIGURE 9 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, END USER SEGMENT ATTRACTIVENESS, 2022-2032 (USD BILLION)
• FIGURE 10 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER, 2022 & 2032 (USD BILLION)
• FIGURE 11 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET SHARE (%), BY END USER,
• FIGURE 12 GLOBAL: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION, 2022 & 2032 (USD BILLION)
• FIGURE 13 GLOBAL: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET SHARE (%), BY REGION,
• FIGURE 14 NORTH AMERICA STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, 2019-2032 (USD BILLION)
• FIGURE 15 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
• FIGURE 16 NORTH AMERICA: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET SHARE (%), BY COUNTRY,
• FIGURE 17 EUROPE STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, 2019-2032 (USD BILLION)
• FIGURE 18 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
• FIGURE 19 EUROPE: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET SHARE (%), BY COUNTRY,
• FIGURE 20 ASIA-PACIFIC MARKET ANALYSIS: TWO-PIECE EMPTY HARD CAPSULE MARKET, 2019-2030 (USD BILLION)
• FIGURE 21 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY COUNTRY, 2022 & 2032 (USD BILLION)
• FIGURE 22 ASIA-PACIFIC: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET SHARE (%), BY COUNTRY,
• FIGURE 23 REST OF THE WORLD MARKET ANALYSIS: STAPHYLOCOCCUS AUREUS INFECTIONS FOR ORTHOPEDIC IMPLANT MARKET, 2019-2032 (USD BILLION)
• FIGURE 24 REST OT THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION, 2022 & 2032 (USD BILLION)
• FIGURE 25 REST OT THE WORLD: STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET SHARE (%), BY REGION,
• FIGURE 26 STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET PLAYERS: COMPETITIVE ANALSIS,
• FIGURE 27 COMPETITOR DASHBOARD: GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET
• FIGURE 28 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 29 MERCK KGAA: SWOT ANALYSIS
• FIGURE 30 THERMO FISHER SCIENTIFIC INC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 31 THERMO FISHER SCIENTIFIC INC: SWOT ANALYSIS
• FIGURE 32 BIOMERIEUX SA: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 33 BIOMERIEUX SA: SWOT ANALYSIS
• FIGURE 34 SIEMENS HEALTHINEERS AG: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 35 SIEMENS HEALTHINEERS AG: SWOT ANALYSIS
• FIGURE 36 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 37 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
• FIGURE 38 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
• FIGURE 39 PFIZER INC: SWOT ANALYSIS

Global Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market Research Report Information by Diagnosis & Treatment {(Diagnosis [Microbiological Culture Test, Polymerase Chain Reaction, and Imaging Studies {Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and Ultrasonography}], Treatment(Antibiotics, Antimicrobial Therapy, and Surgery)}, by End User (Hospitals, Ambulatory Surgery Centers, and Others), by Region (North America, Europe, Asia-Pacific, and Rest of the World) Forecast till 2032

Market Overview

Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implants The market was valued at USD 2.31 billion in 2022. The staphylococcus aureus infection diagnostics and treatment for orthopedic implants market is expected to increase from USD 2.40 billion in 2023 to USD 3.87 billion by 2032, with a compound yearly growth rate (CAGR) of 4.89% over the forecast period. The increasing number of orthopedic procedures involving implants, as well as the increased incidence of fractures, are driving market expansion.

The growing number of orthopedic procedures is driving up the demand for staphylococcus aureus infection diagnosis and treatment for orthopedic implants. For example, in July 2023, Cleveland Clinic (US) announced that approximately 800,000 knee replacements are performed annually in the United States. Furthermore, the American Association of Hip and Knee Surgeons identifies prosthetic joint infection (PJI) as a serious concern following total hip arthroplasty (THA), particularly when other health issues are present, which increases the risk. The rate of infections caused by staphylococcus aureus increased from 26.3% in 2008-2009 to 40% between 2020 and 2021.

Market Segment insights

The Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is classified by diagnosis and treatment, with diagnosis further subdivided into microbiological culture test, polymerase chain reaction, and imaging studies.

The Staphylococcus aureus Infection Diagnosis and Treatment for Orthopedic Implant Market is segmented by end user, which includes hospitals, ambulatory surgical centers, and others.

Regional insights

The report divides the market into five regions: the United States, Europe, China, the Middle East and North Africa, and the rest of the world. In 2022, the North American staphylococcus aureus infection diagnostic and treatment for orthopedic implants market held the greatest market share. This is related to the increased prevalence of staphylococcus aureus infection in orthopedic implants, excellent healthcare infrastructure, and an increase in the number of orthopedic procedures in North America.

The Europe staphylococcus aureus infection detection and treatment for orthopedic implants market has the second-largest market share due to an increasing elderly population and favorable reimbursement policies across the country. Furthermore, Germany has the largest market share for staphylococcus aureus infection diagnosis and treatment for orthopedic implants, while the UK is expected to be the fastest-growing market in the European region.

The Asia-Pacific staphylococcus aureus infection diagnostic and treatment market for orthopedic implants is predicted to develop significantly between 2023 and 2032. This is attributable to strong population increase, government initiatives and investments, and coordination among regional healthcare partners.

The rest of the world is divided into three regions: the Middle East, Africa, and Latin America. The staphylococcus aureus infection diagnosis and treatment for orthopedic implants market in the regions is expected to increase as a result of continuing research & development activities to create novel diagnostic technologies, medicines, and preventive methods.

Major Players

Xellia Pharmaceuticals (Germany), Wellona Pharma (India), Schwitz Biotech (India), Merck KGaA (Germany), Thermo Fisher Scientific Inc (US), BioMerieux SA (France), Siemens Healthineers AG (Germany), Beckman Coulter Inc (US), Hoffmann-La Roche Ltd (Switzerland), and Pfizer Inc (US) are among the key companies in the Staphylococcus Aureus Infection Diagnosis and Treatment for Orthopedic Implant Market.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

• 2.1 DEFINITION
• 2.2 SCOPE OF THE STUDY
• 2.3 RESEARCH OBJECTIVE
• 2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

• 3.1 OVERVIEW
• 3.2 DATA FLOW
  • 3.2.1 Data Mining Process
• 3.3 PURCHASED DATABASE:
• 3.4 SECONDARY SOURCES:
  • 3.4.1 Secondary Research data flow:
• 3.5 PRIMARY RESEARCH:
  • 3.5.1 Primary Research DATA FLOW:
  • 3.5.2 Primary Research: Number of Interviews conducted
  • 3.5.3 Primary Research: Regional Coverage
• 3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
  • 3.6.1 Revenue Analysis Approach
• 3.7 DATA FORECASTING
  • 3.7.1 Data forecasting Technique
• 3.8 DATA MODELING
  • 3.8.1 microeconomic factor analysis:
  • 3.8.2 Data modeling:
• 3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

• 4.1 INTRODUCTION
• 4.2 DRIVERS
  • 4.2.1 Growing number of Orthopedic surgeries associated with implants
  • 4.2.2 Increasing incidence of fractures
• 4.3 RESTRAINTS
  • 4.3.1 Stringent regulatory requirements and lengthy approval processes
• 4.4 OPPORTUNITY
  • 4.4.1 Technological treatment for orthopedic associated staphylococcus aureus infection
  • 4.4.2 Growing awareness of early diagnosis and the development of early diagnosis products

5 MARKET FACTOR ANALYSIS

• 5.1 PORTER'S FIVE FORCES MODEL
  • 5.1.1 Threat of New Entrants
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 Threat of Substitutes
  • 5.1.4 Bargaining Power of Buyers
  • 5.1.5 Intensity of Rivalry
• 5.2 IMPACT OF COVID-19 ON THE GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET
• 5.3 QUALITATIVE OVERVIEW ON TREATMENT MANAGEMENT FOR STAPHYLOCOCCUS AUREUS BEFORE CULTURE AND ITS IMPACT ON HEALTHCARE COST
• 5.4 INDICATIVE SHARE (%) FOR IMPLANTS AFFECTED BY STAPHYLOCOCCUS AUREUS BY REGION, (2022)
• 5.5 TOTAL NUMBER OF JOINT REPLACEMENTS AND COMPLICATED FRACTURES REPAIRED WITH PLATES AND SCREWS
• 5.6 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED.
• 5.7 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS INFECTED WITH STAPHYLOCOCCUS AUREUS (SA) INFECTION
• 5.8 TOTAL NUMBER OF COMPLICATED FRACTURES AND JOINT REPLACEMENTS REVISED SURGERIES ARE DONE BASED ON AN SA INFECTION
• 5.9 TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES AND TOTAL NUMBER OF SYNOVIAL FLUID PUNCTURES INFECTED WITH SA

6 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY DIAGNOSIS & TREATMENT

• 6.1 OVERVIEW
• 6.2 DIAGNOSIS
  • 6.2.1 Microbiological Culture Test
  • 6.2.2 Polymerase Chain Reaction
  • 6.2.3 Imaging Studies
    • 6.2.3.1 Computed Tomography (CT)
    • 6.2.3.2 Magnetic Resonance Imaging (MRI)
    • 6.2.3.3 Ultrasonography
• 6.3 TREATMENT
  • 6.3.1 Antibiotics
  • 6.3.2 Antimicrobial Therapy
  • 6.3.3 Surgery

7 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY END USER

• 7.1 OVERVIEW
• 7.2 HOSPITALS
• 7.3 AMBULATORY SURGERY CENTERS
• 7.4 OTHERS

8 GLOBAL STAPHYLOCOCCUS AUREUS INFECTION DIAGNOSIS AND TREATMENT FOR ORTHOPEDIC IMPLANT MARKET, BY REGION

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 us
  • 8.2.2 canada
• 8.3 EUROPE
  • 8.3.1 germany
  • 8.3.2 France
  • 8.3.3 UK
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 ASIA-PACIFIC
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 South Korea
  • 8.4.5 australia
  • 8.4.6 Rest of Asia-Pacific
• 8.5 REST OF THE WORLD
  • 8.5.1 Middle East & Africa
  • 8.5.2 Latin America

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 MARKET SHARE ANALYSIS,
• 9.3 COMPETITOR DASHBOARD
• 9.4 PUBLIC PLAYERS STOCK SUMMARY
• 9.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
• 9.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
  • 9.6.1 Product approval

10 COMPANY PROFILES

• 10.1 XELLIA PHARMACEUTICALS
  • 10.1.1 COMPANY OVERVIEW
  • 10.1.2 FINANCIAL OVERVIEW
  • 10.1.3 PRODUCTS OFFERED
  • 10.1.4 KEY DEVELOPMENTS
  • 10.1.5 KEY STRATEGIES
• 10.2 WELLONA PHARMA
  • 10.2.1 COMPANY OVERVIEW
  • 10.2.2 FINANCIAL OVERVIEW
  • 10.2.3 PRODUCTS OFFERED
  • 10.2.4 KEY DEVELOPMENTS
  • 10.2.5 KEY STRATEGIES
• 10.3 SCHWITZ BIOTECH
  • 10.3.1 COMPANY OVERVIEW
  • 10.3.2 FINANCIAL OVERVIEW
  • 10.3.3 PRODUCTS OFFERED
  • 10.3.4 KEY DEVELOPMENTS
  • 10.3.5 KEY STRATEGIES
• 10.4 MERCK KGAA
  • 10.4.1 COMPANY OVERVIEW
  • 10.4.2 FINANCIAL OVERVIEW
  • 10.4.3 Products OFFERed
  • 10.4.4 KEY DEVELOPMENTS
  • 10.4.5 SWOT ANALYSIS
  • 10.4.6 KEY STRATEGIES
• 10.5 THERMO FISHER SCIENTIFIC INC
  • 10.5.1 COMPANY OVERVIEW
  • 10.5.2 FINANCIAL OVERVIEW
  • 10.5.3 products OFFERed
  • 10.5.4 KEY DEVELOPMENTS
  • 10.5.5 SWOT ANALYSIS
  • 10.5.6 Key Strategy
• 10.6 BIOMERIEUX SA
  • 10.6.1 COMPANY OVERVIEW
  • 10.6.2 FINANCIAL OVERVIEW
  • 10.6.3 products OFFERed
  • 10.6.4 KEY DEVELOPMENTS
  • 10.6.5 SWOT ANALYSIS
  • 10.6.6 Key Strategy
• 10.7 SIEMENS HEALTHINEERS AG
  • 10.7.1 COMPANY OVERVIEW
  • 10.7.2 FINANCIAL OVERVIEW
  • 10.7.3 products OFFERed
  • 10.7.4 KEY DEVELOPMENTS
  • 10.7.5 SWOT ANALYSIS
  • 10.7.6 Key Strategy
• 10.8 BECKMAN COULTER INC
  • 10.8.1 COMPANY OVERVIEW
  • 10.8.2 FINANCIAL OVERVIEW
  • 10.8.3 PRODUCTS OFFERED
  • 10.8.4 KEY DEVELOPMENTS
  • 10.8.5 KEY STRATEGIES
• 10.9 F. HOFFMANN-LA ROCHE LTD
  • 10.9.1 COMPANY OVERVIEW
  • 10.9.2 FINANCIAL OVERVIEW
  • 10.9.3 PRODUCTS OFFERED
  • 10.9.4 KEY DEVELOPMENTS
  • 10.9.5 SWOT ANALYSIS
  • 10.9.6 KEY STRATEGIES
• 10.10 PFIZER INC
  • 10.10.1 COMPANY OVERVIEW
  • 10.10.2 FINANCIAL OVERVIEW
  • 10.10.3 productS OFFERED
  • 10.10.4 KEY DEVELOPMENTS
  • 10.10.5 SWOT ANALYSIS
  • 10.10.6 KEY STRATEGIES

11 DATA CITATIONS